DURECT Corporation Invites You to View Its Chase H&Q Healthcare Conference Investor Presentation

Download PDF:

CUPERTINO, Calif., Dec. 12 /PRNewswire/ — DURECT Corporation
(Nasdaq: DRRX) today announced that it will present a company overview and
discuss the Phase II trial in progress for its lead product, DUROS sufentanil
for the treatment of chronic pain, at the 19th Annual Healthcare Conference to
be held January 9, 2001 at 2:00 P.M. in San Francisco, CA at the Westin St.
Francis Hotel. The presentation will be webcast live from the Chase H&Q
Healthcare Conference. The webcast will be available on DURECT’s website at
http://www.www.durect.com under the Calendar of Event section of “Investor
Relations.” The presentation will also be available for replay on DURECT’s
website for a period of one week after the conference. To join DURECT’s email
alert service and receive advance notice of these and other events, please
register by selecting “Email Alerts” on the main Investor Relations web page
at http://www.www.durect.com.

DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems to deliver the right drug to the right site in the
right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.
DURECT’s initial portfolio of products combine the DUROS technology, a proven
and patented drug delivery platform licensed for specified fields of use from
ALZA Corporation, with drugs for which medical data on efficacy and safety are
available. Founded in 1998, the Company is headquartered in Cupertino, CA. The
Company’s World Wide Web site can be accessed at http://www.www.durect.com. To
join DURECT’s email alert service, please register by selecting “Email Alerts”
on the main Investor Relations web page at http://www.www.durect.com

DUROS is a registered trademark of ALZA Corporation.

The statements in this press release regarding DURECT’s products in
development, product development plans, clinical trials, and expected product
benefits are forward-looking statements involving risks and uncertainties that
could cause actual results to differ materially from those in such forward-
looking statements. Potential risks and uncertainties include, but are not
limited to, DURECT’s ability to develop, manufacture and commercialize its
products, complete successful clinical trials, obtain product approvals from
regulatory agencies, build a manufacturing facility, marketplace acceptance of
DURECT’s products and DURECT’s ability to manage its growth and costs. Further
information regarding these and other risks is included in the company’s S-1
registration statement, filed with the SEC on September 22, 2000, its 424(b)
prospectus filed with the SEC on September 28, 2000 and its Quarterly Report
on Form 10Q for the quarter ended September 30, 2000 filed with the SEC on
November 13, 2000.

CONTACT: Schond L. Greenway, Director, Investor Relations of DURECT
Corporation, 408-777-1417, Schond.Greenway@Durect.com; or Tom Baker Media
Relations of Noonan-Russo Communications, 415-677-4455 ext. 370, for DURECT

Scroll to Top